Skip to content
Biodatica
Start free

Shenzhen TargetRx Co., Ltd.

Beijing, Beijing Municipality

OncologyPhase III
Compare Sign in to watch

What changed

Phase III trial registered: Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax

5mo agoTrial registeredFeb 12, 2026Source filing (opens the source filing in a new tab)

Momentum

67no change

Momentum 67 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

620 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE3 registered

    Feb 1, 2026

    Acute Myeloid Leukemia · NOT_YET_RECRUITING · sponsor: Peking University People's Hospital · Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax

    ClinicalTrials.gov · NCT07407660 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    Jul 15, 2024

    Chronic Myeloid Leukemia, Accelerated Phase CML · RECRUITING · sponsor: Shenzhen TargetRx Co., Ltd. · TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients

    ClinicalTrials.gov · NCT06453902 (opens the source filing in a new tab)

  3. Trial

    Study registered

    Jul 1, 2024

    Chronic Myeloid Leukemia · RECRUITING · sponsor: Peking University People's Hospital · The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP

    ClinicalTrials.gov · NCT06390306 (opens the source filing in a new tab)

  4. Trial

    PHASE1 registered

    Mar 29, 2021

    Chronic Myelogenous Leukemia · ACTIVE_NOT_RECRUITING · sponsor: Shenzhen TargetRx Co., Ltd. · TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients

    ClinicalTrials.gov · NCT05434312 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources